ClinicalTrials.gg
Not yet recruitingNCT07279142HYPNOSUpdated Dec 12, 2025

Efficacy and Safety of 7 Millimeters Vaginal Radiofrequency in Overactive Bladder

An interventional study of Radiofrequency in Overactive Bladder (OAB) and Incontinence, Urge, sponsored by IRCCS San Raffaele. Not yet recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by IRCCS San Raffaele · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Urinary Bladder, Overactive with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Urinary Bladder, Overactive · Italy.

Planned enrollment
23rd of 24
48 · median 884
Started
2025
with 1 other
No phase
2 of 30
1 open now
Registered
29th of 30
by date
Lead sponsor
1 of 30
IRCCS San Raffaele

Among the 30 studies in Urinary Bladder, Overactive with a site in Italy, this one is the 23rd largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 with no phase, and was the 29th registered.

Urinary Bladder, Overactive

861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

3 of the 30 studies in Urinary Bladder, Overactive with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Urinary Bladder, Overactive with a site in Italy, or all of them as a file.
02

Study summary

The investigator hypothesizes that controlled delivery of low heat (45-50 Centigrade) to the sub-detrusor and detrusor muscle can ablate the autonomic nerve endings and control overactive bladder symptoms without causing significant damage to the surrounding structures. Low heat in such a manner is below urethral sensation and enables office treatment. The transvaginal approach is non-invasive and improves overactive bladder (OAB) symptoms and patients' quality of life. The investigator believes that the RF administration results could be equal or better for first-line treated patients compared to pharmacological refractory patients.

03

Conditions studied

  • Overactive Bladder (OAB)
  • Incontinence, Urge
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age>18 years old
  • Subject is willing to provide , is geographically stable, understands the requirements for completing the bladder diary and is willing to comply with the required diary, follow-up visits, and testing schedules.
  • Urinary incontinence, predominant urgency incontinence, with moderate-severe overactive bladder, International Consultation on Incontinence Questionnaire - Overactibe Bladder Short Form (ICIQ-OABSS) score ≥6.
  • Ability and willingness to self-catheterize in case this is necessary.
  • With respect to their reproductive capacity must be or surgically sterile or willing to use a method with a failure rate of less than 1% per year when used consistently and correctly from screening until the last follow up

Exclusion criteria

Exclusion Criteria:

  • Pacemaker or internal defibrillator, or any other metallic or electronic implant anywhere in the body.
  • Any permanent implant or an injected chemical substance in the treatment area.
  • Superficial areas that have been injected with hyaluronic acid (HA)/collagen/fat injections or other augmentation methods with bio-material during last 6 months.
  • Current or history of cancer, or current condition of any other type of cancer, or premalignant moles.
  • Severe concurrent conditions, such as cardiac disorders, sensory disturbances, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
  • Pregnancy, the intention of pregnancy and nursing.
  • Impaired immune system due to diseases such as Acquired Immunodeficency Syndrome (AIDS) and Human Immunodeficency Virus (), disorders, or use of immunosuppressive medications.
  • Patients with a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen.
  • Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.
  • Any active condition in the treatment area, such as sores, eczema, and rash.
  • History of vaginal disorders, keloids, abnormal wound healing.
  • History of bleeding coagulopathies or use of anticoagulants in the last 10 days, as per the practitioner's discretion.
  • Non-italian speakers
  • Severely impaired mobility or cognition
  • Spinal cord injury or advanced/severe neurologic condition including Multiple Sclerosis, Parkinson's Disease
  • Repair of pelvic organ prolapse or incontinence procedure in the previous 6 months
  • Ongoing complications of prior anti-incontinence surgery
  • Received intravesical botulinum injection within the previous 12 months
  • History of an implanted nerve stimulator for incontinence
  • History of prior sling or vaginal mesh placement,
  • Previous diagnosis of interstitial cystitis, bladder cancer, or chronic pelvic pain
  • Current participation in any other conflicting interventional or OAB treatment study
  • Planning to become pregnant during the study period.
  • Pelvic radiation, history of pelvic radiation
  • Active urinary tract or vaginal infection
  • Anatomical conditions that would prevent the introduction and use of the device, in such as significant pelvic organ prolapse,
  • Current hydronephrosis or hydroureter
  • Bladder outflow obstruction
  • Active pelvic organ
  • Urethral obstruction
  • Urinary retention or prolonged catheter use
  • Less than 12 months post-partum or currently pregnant or plan to become pregnant in the following 12 months.
  • Untreated symptomatic urinary tract infection
  • Unevaluated hematuria
  • Medical instability
  • Allergy to anesthetics as Benzocaine/Lidocaine/Tetracaine Cream (BLT Cream) used in the study
  • Not available for follow-up in 6 months
  • Participation in other research trials that could influence results of this study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    patients who have never received pharmacological or medical device treatment for OAB

    Transvaginal micro-radiofrequency with 7mm needles in patients who have never received pharmacological or medical device treatment for OAB (first-line group).

    Device: Radiofrequency

  • Experimental
    patients who have failed adequate therapy (≥12 weeks) with antimuscarinics

    Transvaginal micro-radiofrequency with 7 mm needles in patients who have failed adequate therapy (≥12 weeks) with antimuscarinics due to ineffectiveness, intolerance or contraindications (refractory group)

    Device: Radiofrequency

Interventions

  • DeviceRadiofrequency

    According to the study protocol, eligible subjects will receive one treatment within 3 weeks of screening. After one month, if there is no satisfactory result, a second treatment will be administered, and after another month, the patient will be evaluated. If there is still no end point, a third treatment will be given. It should be noted that the second and third treatments will only be performed if there is no satisfactory result after the previous treatment. Treatment area: Treatment area will include vaginal canal. Treatment Procedure: * Subjects receive HYPNOS treatment with device using radiofrequency (RF). Treat vaginal canal at the depth starting from approximately 3.5cm from introitus to the distal end of vagina. Radially the treatment area is from 9 to 3 o'clock. * Patient should empty bladder prior to treatment * Position patient in lithotomy position * Set energy to levels well tolerated by the subject. Suggested settings: Burst Mode 7mm, 1 pass.

06

What researchers measure

Primary outcomes

  1. Improvement of 40% in the Overactive Bladder Symptoms Bother Questionnaire Score Short Form from the baseline score

    Time frame: From enrollment to 12 weeks after last treatment

07

Study locations

1 site
08

References and documents

Publications

  • Rovner ES, Versi E, Le Mai T, Dmochowski RR, De Wachter S. One-year results with selective bladder denervation in women with refractory overactive bladder. Neurourol Urodyn. 2019 Nov;38(8):2178-2184. doi: 10.1002/nau.24110. Epub 2019 Jul 29. PubMed 31359508 ↗
  • Abdelaziz A, Dell J, Karram M. Transvaginal radiofrequency energy for the treatment of urinary stress incontinence: A comparison of monopolar and bipolar technologies in both pre- and post-menopausal patients. Neurourol Urodyn. 2021 Sep;40(7):1804-1810. doi: 10.1002/nau.24748. Epub 2021 Jul 20. PubMed 34288106 ↗
  • Cespedes RD, Cross CA, McGuire EJ. Modified Ingelman-Sundberg bladder denervation procedure for intractable urge incontinence. J Urol. 1996 Nov;156(5):1744-7. PubMed 8863585 ↗
  • Dayan E, Ramirez H, Westfall L, Theodorou S. Role of Radiofrequency (Votiva, InMode) in Pelvic Floor Restoration. Plast Reconstr Surg Glob Open. 2019 Apr 25;7(4):e2203. doi: 10.1097/GOX.0000000000002203. eCollection 2019 Apr. PubMed 31321190 ↗
  • Takahashi T, Garcia-Osogobio S, Valdovinos MA, Belmonte C, Barreto C, Velasco L. Extended two-year results of radio-frequency energy delivery for the treatment of fecal incontinence (the Secca procedure). Dis Colon Rectum. 2003 Jun;46(6):711-5. doi: 10.1007/s10350-004-6644-8. PubMed 12794570 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2025; primary completion for Nov 2026, 10 months later.

Of 135 non-industry interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 10 months is below that.

Counting every sponsor, half of 176 studies reached it within 19 months; a quarter within 10 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Dec 12, 2025
StartEst.
Dec 16, 2025
Primary completionEst.
Nov 13, 2026
CompletionEst.
Dec 24, 2026
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07279142
Lead sponsor
IRCCS San Raffaele
Responsible party
Stefano Salvatore (Professor, IRCCS San Raffaele) — Principal investigator
First posted
Dec 12, 2025
Start date
Dec 16, 2025 (estimated)
Primary completion
Nov 13, 2026 (estimated)
Completion
Dec 24, 2026 (estimated)
Last update
Dec 12, 2025

Study contacts

Stefano Salvatore Professor
Contact
salvatore.stefano@hsr.it
0039 3472757131

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion